Mosaicism. That is the word now hanging over the future of human embryo gene editing. Dr. Dieter Egli of Columbia University fixed individual genetic letters in human embryos using a technique called base editing. But he did not fix all of them. In some cells, the editing molecules missed their target entirely. The result was embryos that were genetic patchworks — some cells altered, others unchanged.
That mixture, known as mosaicism, is not a minor technical hitch. If an embryo carrying a mix of edited and unedited genes were ever allowed to develop into a baby, the medical consequences could be serious. A child might have some organs with the corrected gene and others without. Diseases could manifest unevenly. Treatments designed for a uniform genetic fix would fail.
The work, reported in The New York Times, revives a debate that has never really gone quiet. It flared into global condemnation in 2018, when a Chinese scientist announced the birth of gene-edited babies. The scientific community reacted with fury. Governments moved to restrict or ban clinical use of the technology. Mainstream bodies, including leading scientific organizations, still hold that germline editing is not safe for pregnancies. Dr. Egli’s results do nothing to change that position.
What they do is show how fast the field is moving. Base editing is a more targeted approach than earlier gene-editing tools. It swaps out individual letters in the DNA sequence rather than cutting both strands of the double helix. That should be safer. But precision is not perfection. The editing molecules failed to reach their targets in some cells, and the embryos became mosaics.
The ethical questions are not abstract. They are embedded in every cell of those embryos. If the technology ever reaches a clinic, a doctor would have to tell a prospective parent that the child might carry a mix of edited and unedited genes. That parent would have to decide whether to proceed. There is no data on what that decision would mean for the child’s health. There are no long-term studies. There are no guarantees.
Researchers like Dr. Egli are pushing forward anyway. The potential payoff is large. Genetic diseases that run in families could be stopped before a child is born. A single edit in an embryo could spare a person a lifetime of illness. That is the promise. But the path to that promise is littered with embryos that are not fully edited, with cells that resist change, with molecules that miss their marks.
The 2018 scandal still shapes the landscape. That Chinese scientist drew international condemnation, and the fallout has been lasting. Countries tightened rules. Funding agencies became cautious. The public grew skeptical. Dr. Egli’s work, for all its technical sophistication, lands in that atmosphere. It is progress. It is also a reminder of how far the field is from clinical reality.
Mosaicism is not the only obstacle. Safety is the headline. But there are deeper questions about what kind of future is being built. If the technology matures, who decides which genes are worth editing? What counts as a disease versus a variation? Those conversations are happening in ethics committees and university halls, but they are not settled. They may never be fully settled.
For now, the embryos remain in the lab. No one is proposing to implant them. The mainstream scientific position is clear: not safe, not ready. But the work continues. Each new study pushes the boundary a little further. Each new result forces the debate to sharpen. Mosaicism is a technical problem. The ethical problem is larger. And it is not going away.
